NASDAQ · Drug Manufacturers - Specialty & Generic · USD
Incannex Healthcare Inc. (IXHL) Stock Analysis
Incannex Healthcare Inc. (IXHL) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
IXHL Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.78
- Previous Close
- $2.75
- Day's Range
- 2.75–2.81
- 52-Week Range
- 2.49–14.91
- Volume
- 30.72K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 2.82
Valuation
- Market Cap
- $34.62M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.66
Financials (FY)
- Revenue (FY)
- $12.00K
- Net Income (FY)
- −$18.46M
- Shares Outstanding
- 12.54M
- 1-Year Return
- −74.23%
Dividend and dates
- Avg Volume
- 85.17K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, IXHL closed at $2.76, −74.23% over 1 year.
Incannex Healthcare Inc. (IXHL) has a market capitalization of $34.62M.
In fiscal 2024, IXHL reported revenue of $12.00K.
IXHL Stock Return by Calendar Year
Incannex Healthcare Inc. (IXHL) return since Mar 2022: what $10,000 became
- 1 year
- $10,000 $2,577
- −74.23%
- 3 years
- $10,000 $256
- −97.44%
- Since Mar 2022
- $10,000 $15
- −99.85%
If you had invested $10,000 in Incannex Healthcare Inc. (IXHL) at the close on March 2, 2022, the earliest close on record here, it would have been worth $15 at the close on October 21, 2026: −99.85% in total, −75.23% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −74.30% |
| 2025 | −83.11% |
| 2024 | −54.31% |
| 2023 | −58.57% |
| 2022 (partial year) | −81.18% |
As of October 21, 2026.
IXHL Revenue and Earnings by Fiscal Year
FY ends June| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2024 | $12.00K | −$18.46M | −153,825.0% |
| 2023 | $0.00 | −$48.81M | — |
| 2022 | $0.00 | −$10.25M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2024 | $12.00K | — | −$18.61M | −$18.46M | −153,825.0% |
| 2023 | $0.00 | $0.00 | −$13.64M | −$48.81M | — |
| 2022 | $0.00 | −$4.36K | −$10.16M | −$10.25M | — |
Annual figures as reported, in the company's reporting currency. As of June 30, 2024.
Recent News
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
YahooIncannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position
YahooIncannex Healthcare Receives Final A$5.1M R&D Tax Incentive Refund Following Approval Of Its Overseas Findings And Amendment Of Its FY25 Tax Return
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Drug Manufacturers - Specialty & Generic Stocks
Takeda Pharmaceutical Company Limited
$63.67B
TEVATeva Pharmaceutical Industries Limited
$47.37B
HLNHaleon plc
$44.06B
ZTSZoetis Inc.
$32.90B
UTHRUnited Therapeutics Corporation
$24.17B
VTRSViatris Inc.
$21.19B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B